Navigation Links
New DNA and RNA aptamers offer unique therapeutic advantages
Date:8/5/2009

New Rochelle, NY, August 5, 2009A novel class of drugs composed of single strands of DNA or RNA, called aptamers, can bind protein targets with a high strength and specificity and are currently in clinical development as treatments for a broad range of common diseases, as described in a comprehensive review article published online ahead of print in Oligonucleotides, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The article is available free online at www.liebertpub.com/oli

Aptamers offer several advantages compared to protein or small molecule drugs, most notably their ease of production, low risk of inducing an immune reaction in humans, and amenability to chemical modifications that enhance their drug-like properties, including improved stability and residence time in the bloodstream. Aptamer therapeutics presently in clinical development target diseases and applications such as macular degeneration, coronary artery bypass graft surgery, and various types of cancer.

Kristina W. Thiel, PhD and Paloma H. Giangrande, PhD, from the University of Iowa, present a thorough review of aptamers and aptamer-based therapeutic strategies that have the highest likelihood of success. In the article entitled "Therapeutic Applications of DNA and RNA Aptamers," the authors describe the methods used to identify aptamers that specifically bind protein drug targets of interest, the types of modifications that have been made to aptamers to enhance their therapeutic potential, and the different types of aptamers that are currently in development. They also discuss the challenges that must still be overcome for aptamer technology to achieve its full potential.

"This is a comprehensive and timely review of aptamer development and therapeutic applications that our readers should enjoy," says John Rossi, PhD, Co-Editor-in-Chief of Oligonucleotides and Professor in the Department of Molecular Biology, Beckman Research Institute of the City of Hope (Duarte, CA).


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Related biology news :

1. M2SYS Technology to Offer Desktop Biometric Technology to Kronos Customers
2. New lab test offers better prediction of HIV microbicide safety
3. Biological warfare in bacteria offers hope for new antibiotics
4. MS study offers theory for why repair of brains wiring fails
5. M2SYS Technology to Offer Desktop Biometric Technology to Kronos Customers
6. Embryology study offers clues to birth defects
7. Stem cell protein offers a new cancer target
8. Validus and HierStar Form Strategic Alliance to Offer the First Complete Range of Authentication Products
9. ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor
10. Novel vaccine approach offers hope in fight against HIV
11. MIT’s implantable device offers continuous cancer monitoring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
(Date:4/13/2017)... -- According to a new market research report "Consumer IAM ... and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global ... grow from USD 14.30 Billion in 2017 to USD 31.75 Billion by ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
Breaking Biology News(10 mins):
(Date:9/14/2017)... UK (PRWEB) , ... September 14, 2017 , ... ... most innovative minds in pharma and biotech at the third annual DrugDev Summit, ... conference that brings together the world’s most progressive clinical research leaders for best ...
(Date:9/14/2017)... ... September 14, 2017 , ... One of the world’s largest World Marrow Donor ... six hours that day, the GenCure Marrow Donor Program will be signing up potential ... stores in San Antonio. , The registration tables will be staffed by employees from ...
(Date:9/13/2017)... ... September 13, 2017 , ... PRC Clinical and SDC ... 21st from 6 to 8:30pm EDT at Catalyst in Cambridge, MA. , ... Operations Professionals.” From tracking enrollment progress to communicating with underperforming sites to engaging ...
(Date:9/12/2017)... ... September 12, 2017 , ... It wasn’t just the San Diego ... hot, hot, hot, as Lajollacooks4u has had a record-breaking number of guests for corporate ... far and wide to celebrate company outings, family get-togethers, anniversaries and milestone birthdays. ...
Breaking Biology Technology: